These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 35773148)

  • 41. Next generation patient derived tumor organoids.
    Podaza E; Kuo HH; Nguyen J; Elemento O; Martin ML
    Transl Res; 2022 Dec; 250():84-97. PubMed ID: 35964899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Organoid technology and applications in cancer immunotherapy and precision medicine.
    Homicsko K
    Curr Opin Biotechnol; 2020 Oct; 65():242-247. PubMed ID: 32603978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A synopsis of prostate organoid methodologies, applications, and limitations.
    Gleave AM; Ci X; Lin D; Wang Y
    Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging organoid models: leaping forward in cancer research.
    Fan H; Demirci U; Chen P
    J Hematol Oncol; 2019 Dec; 12(1):142. PubMed ID: 31884964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor organoids: Opportunities and challenges to guide precision medicine.
    Veninga V; Voest EE
    Cancer Cell; 2021 Sep; 39(9):1190-1201. PubMed ID: 34416168
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
    Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
    Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pan-cancer organoid platform for precision medicine.
    Larsen BM; Kannan M; Langer LF; Leibowitz BD; Bentaieb A; Cancino A; Dolgalev I; Drummond BE; Dry JR; Ho CS; Khullar G; Krantz BA; Mapes B; McKinnon KE; Metti J; Perera JF; Rand TA; Sanchez-Freire V; Shaxted JM; Stein MM; Streit MA; Tan YC; Zhang Y; Zhao E; Venkataraman J; Stumpe MC; Borgia JA; Masood A; Catenacci DVT; Mathews JV; Gursel DB; Wei JJ; Welling TH; Simeone DM; White KP; Khan AA; Igartua C; Salahudeen AA
    Cell Rep; 2021 Jul; 36(4):109429. PubMed ID: 34320344
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer.
    Toshimitsu K; Takano A; Fujii M; Togasaki K; Matano M; Takahashi S; Kanai T; Sato T
    Nat Chem Biol; 2022 Jun; 18(6):605-614. PubMed ID: 35273398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Next-Generation Modeling of Cancer Using Organoids.
    Love JR; Karthaus WR
    Cold Spring Harb Perspect Med; 2024 Jun; 14(6):. PubMed ID: 37734867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reconstructing the tumor architecture into organoids.
    Luo Z; Zhou X; Mandal K; He N; Wennerberg W; Qu M; Jiang X; Sun W; Khademhosseini A
    Adv Drug Deliv Rev; 2021 Sep; 176():113839. PubMed ID: 34153370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Patient-derived tumor organoids (or tumoroid) as valuable precision medicine tools].
    Perréard M; Florent R; Thorel L; Vincent A; Weiswald LB; Poulain L
    Med Sci (Paris); 2022 Nov; 38(11):888-895. PubMed ID: 36448894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].
    Pauli C; Moch H; Rubin MA
    Pathologe; 2017 Nov; 38(Suppl 2):160-168. PubMed ID: 28956107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microfluidic droplet encapsulation-guided organoid growth promotes parental tumor phenotype recapitulation.
    Zhang W; Jin H; Lou S; Yang H; Dai X; Ma S
    Int J Cancer; 2024 Jan; 154(1):145-154. PubMed ID: 37622267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical investigation of patient-derived cervical cancer organoids for precision medicine.
    Seol HS; Oh JH; Choi E; Kim S; Kim H; Nam EJ
    J Gynecol Oncol; 2023 May; 34(3):e35. PubMed ID: 36659831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Standardization of organoid culture in cancer research.
    Zhou C; Wu Y; Wang Z; Liu Y; Yu J; Wang W; Chen S; Wu W; Wang J; Qian G; He A
    Cancer Med; 2023 Jul; 12(13):14375-14386. PubMed ID: 37081739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Organoid-based personalized medicine: from tumor outcome prediction to autologous transplantation.
    Soto-Gamez A; Gunawan JP; Barazzuol L; Pringle S; Coppes RP
    Stem Cells; 2024 Jun; 42(6):499-508. PubMed ID: 38525972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modeling colorectal cancers using multidimensional organoids.
    Sayed IM; El-Hafeez AAA; Maity PP; Das S; Ghosh P
    Adv Cancer Res; 2021; 151():345-383. PubMed ID: 34148617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Organoids technology for advancing the clinical translation of cancer nanomedicine.
    Zhao DK; Liang J; Huang XY; Shen S; Wang J
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1892. PubMed ID: 37088100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integration of Tumor Microenvironment in Patient-Derived Organoid Models Help Define Precision Medicine of Renal Cell Carcinoma.
    Wang B; Xue Y; Zhai W
    Front Immunol; 2022; 13():902060. PubMed ID: 35592336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.